SecBot SecBot
425 ·Filed Jun 24, 2026

PASG

Passage BIO, Inc.
BEARISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001104659-26-077350
Rule 425 M&A communications
Actionable Insight ▼ Bearish

PASG shareholders face extreme dilution to ~7% ownership; the stock will likely reprice toward the implied stub value plus CVR optionality. Watch for the S-4 registration statement detailing the exchange ratio and any stockholder litigation. The deal's success hinges on REM-422 clinical data readouts in mid-2027 and PIPE closing.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.33
T+0 close · Jun 24, 2026 · via day close
Latest settled
+9.70%
T+60 · $4.75
Vs SPY
+5.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $4.33entry
  2. T+1 · 5mo ago +8.54%α +9.27% · $4.70
  3. T+5 · 5mo ago +5.77%α +4.21% · $4.58
  4. T+20 · 4mo ago +13.16%α +12.64% · $4.90
  5. T+60 · 8w ago +9.70%α +5.97% · $4.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio announced a definitive all-stock merger with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company, while Remix shareholders (including PIPE investors) will own ~93%. The deal is supported by an oversubscribed $100M+ private placement led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead program REM-422, an oral MYB mRNA degrader showing a 43% ORR in adenoid cystic carcinoma. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Pre-merger Passage Bio shareholders expected to own approximately 7% of the combined company at closing.
  • Pre-merger Remix shareholders, including PIPE participants, expected to own approximately 93%.
  • Concurrent oversubscribed private placement led by Decheng Capital with total gross proceeds of over $100M.
  • Combined company expected to have cash runway into 2028.
  • Remix's lead program REM-422 (oral MYB mRNA degrader) showed 43% overall response rate and 100% disease control rate in biomarker-positive ACC patients at RP2D.
  • Closing expected in Q4 2026, subject to stockholder approvals and regulatory clearances.
  • Passage shareholders receive contingent value rights for potential milestone payments from pediatric gene therapy programs sublicensed to Gemma Biotherapeutics.

Financial Impact

Massive dilution for existing Passage shareholders, ownership stake reduced to ~7% of the combined entity. The PIPE of over $100M provides funding into 2028 but primarily benefits Remix stakeholders. CVRs offer speculative upside from legacy gene therapy milestones.

ownership dilutioncash runwaymarket capitalization

Risk Factors

  • Failure to obtain stockholder or regulatory approvals could terminate the merger.
  • REM-422 clinical data may disappoint, undermining the combined company's valuation.
  • PIPE investors may back out if conditions are not met, jeopardizing funding.
  • CVR holders may never receive payments if legacy programs fail to generate milestones.
  • Integration risks and potential shareholder lawsuits could delay or derail the transaction.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
64% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001104659-26-077350
Document: 0001104659-26-077350-index-headers.html0001104659-26-077350
Document: 0001104659-26-077350-index.html0001104659-26-077350
Document: 0001104659-26-077350.txt0001104659-26-077350

Track record

15 reports on PASG

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Viewing Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026